Contact
searchSearch
HMP Global
Login

403

Recent News

News
Five-Year KEYNOTE-942 Results Show Durable Benefit With Intismeran Plus Pembrolizumab in Resected Melanoma
08/27/2026
Stephanie Holland
Five-year results from the phase 2b KEYNOTE-942 trial showed that intismeran plus pembrolizumab maintained durable improvements in recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Five-year results from the phase 2b KEYNOTE-942 trial showed that intismeran plus pembrolizumab maintained durable improvements in recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Five-year results from the phase...
08/27/2026
Oncology
News
Biomarker-Driven GUIDANCE Trial Targets HRD-Positive Small Cell Lung Cancer With Olaparib Plus Durvalumab
08/25/2026
Stephanie Holland
The phase 2 GUIDANCE trial is evaluating maintenance olaparib plus durvalumab in homologous recombination deficiency-positive advanced or metastatic small cell lung cancer after first-line chemoimmunotherapy, testing whether prospective...
The phase 2 GUIDANCE trial is evaluating maintenance olaparib plus durvalumab in homologous recombination deficiency-positive advanced or metastatic small cell lung cancer after first-line chemoimmunotherapy, testing whether prospective...
The phase 2 GUIDANCE trial is...
08/25/2026
Oncology
FDA Approval
FDA Approves Zanidatamab-Based Regimens for First-Line HER2-Positive Advanced Gastroesophageal Adenocarcinoma
08/25/2026
Stephanie Holland
The FDA approved zanidatamab plus chemotherapy, with or without tislelizumab, for first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma after phase 3 HERIZON-GEA-01 data showed significant...
The FDA approved zanidatamab plus chemotherapy, with or without tislelizumab, for first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma after phase 3 HERIZON-GEA-01 data showed significant...
The FDA approved zanidatamab...
08/25/2026
Oncology
News
ESMO Recommends Daraxonrasib After Chemotherapy for RAS G12–Mutant Metastatic Pancreatic Cancer
08/19/2026
Stephanie Holland
ESMO guidelines recommend daraxonrasib as a second-line treatment after chemotherapy for patients with RAS G12–mutant metastatic pancreatic cancer and ECOG performance status 0 to 1, based on phase 3 improvements in survival, response, and...
ESMO guidelines recommend daraxonrasib as a second-line treatment after chemotherapy for patients with RAS G12–mutant metastatic pancreatic cancer and ECOG performance status 0 to 1, based on phase 3 improvements in survival, response, and...
ESMO guidelines recommend...
08/19/2026
Oncology
News
Datopotamab Deruxtecan Delays Quality-of-Life Deterioration Compared With Chemotherapy in HR-Positive, HER2-Negative Breast Cancer
08/19/2026
Emily Estrada
Final safety and patient-reported outcome analyses from the phase 3 TROPION-Breast01 trial showed that datopotamab deruxtecan was associated with fewer grade ≥3 treatment-related adverse events and delayed deterioration in quality of life,...
Final safety and patient-reported outcome analyses from the phase 3 TROPION-Breast01 trial showed that datopotamab deruxtecan was associated with fewer grade ≥3 treatment-related adverse events and delayed deterioration in quality of life,...
Final safety and...
08/19/2026
Oncology
News
Chemotherapy-Free Durvalumab Plus Radiation Meets PFS End Point in Locally Advanced Non-Small Cell Lung Cancer
08/19/2026
Emily Estrada
Results from the phase 2 DART trial showed that concurrent and consolidative durvalumab plus definitive thoracic radiation met the prespecified 2-year progression-free survival benchmark in elderly and frail patients with locally advanced...
Results from the phase 2 DART trial showed that concurrent and consolidative durvalumab plus definitive thoracic radiation met the prespecified 2-year progression-free survival benchmark in elderly and frail patients with locally advanced...
Results from the phase 2 DART...
08/19/2026
Oncology
News
Intismeran Plus Pembrolizumab Outperforms Pembrolizumab Alone in Resected Stage IIB-IV Melanoma
08/19/2026
Stephanie Holland
Topline results from the phase 3 INTerpath-001 trial showed that adjuvant intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Topline results from the phase 3 INTerpath-001 trial showed that adjuvant intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Topline results from the phase 3...
08/19/2026
Oncology
News
Rucaparib Plus Nivolumab Shows Biomarker-Linked Activity in Advanced Biliary Tract Cancer
08/19/2026
Emily Estrada
Results from the phase 2 BilT-02 trial demonstrated that maintenance rucaparib plus nivolumab did not meet the prespecified progression-free survival benchmark in unselected advanced biliary tract cancer after platinum-based chemotherapy but...
Results from the phase 2 BilT-02 trial demonstrated that maintenance rucaparib plus nivolumab did not meet the prespecified progression-free survival benchmark in unselected advanced biliary tract cancer after platinum-based chemotherapy but...
Results from the phase 2 BilT-02...
08/19/2026
Oncology
News
Tisagenlecleucel Shows Durable Five-Year Remissions in Pediatric and Young Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
08/19/2026
Emily Estrada
Five-year results from the phase 2 ELIANA trial showed that tisagenlecleucel produced durable relapse-free and overall survival in heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic...
Five-year results from the phase 2 ELIANA trial showed that tisagenlecleucel produced durable relapse-free and overall survival in heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic...
Five-year results from the phase...
08/19/2026
Oncology
News
Third-Generation Anti-CD30 CAR T-Cell Therapy Shows Durable Responses in Relapsed or Refractory CD30-Positive Lymphoma
08/18/2026
Emily Estrada
Results from a phase 1/2 trial showed that third-generation anti-CD30 CAR T-cell therapy produced high response rates and durable disease control in patients with relapsed or refractory CD30-positive lymphoma, with longer survival observed...
Results from a phase 1/2 trial showed that third-generation anti-CD30 CAR T-cell therapy produced high response rates and durable disease control in patients with relapsed or refractory CD30-positive lymphoma, with longer survival observed...
Results from a phase 1/2 trial...
08/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use